ACE2 expressing HEK293 cells

HEK293 NF-κB-reporter cells expressing the SARS-CoV-2 receptors

InvivoGen offers human embryonic kidney 293 (HEK-293)-derived cell lines, specifically designed for COVID-19 studies:

— HEK-Blue™ hACE2-TMPRSS2 cells

— HEK-Blue™ hACE2 cells

These cells have been engineered to stably overexpress the host SARS-CoV-2 receptors, human (h)ACE2, and TMPRSS2 [1]. They were generated from HEK‑Blue™ Null1‑v cells, which express an NF-κB inducible SEAP (secreted embryonic alkaline phosphatase) reporter gene.

More details

Studying infection and cell fusion with
HEK-Blue™ hACE2-TMPRSS2 cells

Sensitive to SARS-CoV-2

SARS-CoV-2, the causative agent of coronavirus disease-19 (COVID-19), gains entry into host cells through the interaction of the viral Spike protein with the host ACE2 and TMPRSS2 receptors [1]. HEK293-derived cells are poorly permissive to infection by SARS-CoV-2 or Spike pseudotyped lentiviral particles. Therefore, to increase their permissivity HEK-Blue™ Null1-v cells have been stably transfected with ACE2 only, or ACE2 and TMPRSS2. In contrast to HEK-Blue™ Null1-v cells, HEK-Blue™ hACE2(‑TMPRSS2) cells are sensitive to Spike pseudotyped lentiviral particles. Notably, the addition of TMPRSS2 increases the cell line’s infectivity.

For studying Spike-ACE2-dependent cell fusion

These HEK-293-derived SARS-COV-2 permissive reporter cells can be used as ‘acceptor’ cells in InvivoGen’s SARS-CoV-2 Spike-ACE2 dependent cell fusion assay. This relies on the transfer of the TLR/IL-1 adaptor molecule, MyD88, from a 'donor cell line' (293-hMyD88 transfected with a Spike expression plasmid) to an 'acceptor cell line' expressing an NF-κB-SEAP-inducible reporter gene. Cell fusion is readily assessable in the co-culture supernatant using the SEAP detection reagent, QUANTI‑Blue™ Solution. Unlike infection by pseudotyped particles, the presence of TMPRSS2 does not have an effect on cell fusion in this assay.

Key features

• Verified overexpression of human ACE2 and TMPRSS2 genes
• Permissive and sensitive to SARS-COV-2 Spike pseudotyped lentiviral particles
• Functionally tested in InvivoGen’s cell fusion assay with SARS-CoV-2 Spike-expressing hMyD88 cells.
• Readily assessable NF-κB-dependent SEAP reporter activity

Applications

• Screening inhibitors of Spike-binding and/or its host receptors (i.e. ACE2 and TMPRSS2).
• Studying the efficacy of the vaccines and/or current therapeutics (e.g. mAbs) against the emerging variants by infection studies with pseudotyped particles or cell fusion assays.

InvivoGen has also generated:
➔ HEK-Lucia™ hACE2 and HEK-Lucia™ hACE2-TMPRSS2 cells featuring an NF-KB-inducible Lucia luciferase reporter for a larger detection range than the colorimetric SEAP assays.
➔ HEK-hACE2 and HEK-hACE2-TMPRSS2 cells with no reporter activity for infection, pseudoparticle transduction, or qualitative fusion assays.
These cells have been used to compare the efficiency of SARS-CoV2 Spike variant-mediated cellular infection and fusion. See data

Learn more about SARS-CoV-2 infection and potential therapeutics 

References

1. Hoffmann M. et al., 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 181:1-16.
2. Zhou P. et al., 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 579(7798):270-273.
3. Walls A.C. et al., 2020. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 181(2):281-292.e6.

Figures

hACE2 mRNA expression in HEK-Blue™ hACE2 cells. Total mRNA was extracted from ~5x105 HEK-Blue™ Null1-v and HEK‑Blue™ hACE2 cells and ACE2 mRNA was amplified using quantitative (q)RT-PCR. Data are represented as the log₂ fold change comparing hACE2 expression to a housekeeping gene.

Surface expression of hACE2 by HEK-Blue™ hACE2 cells. ~5x10⁵ HEK-Blue™ Null1-v and HEK-Blue™ hACE2 cells were incubated with 1 μg of Spike-S1-Fc or CTLA-4-Fc fusion proteins for 1 hr at 4°C. Cells were then washed and incubated with 0.5 μg of a goat anti-hIgG1-Fc antibody coupled to PE for 1 hr at 4°C. Cell surface staining was analyzed by flow cytometry.

Specific infection of HEK-Blue™ hACE2 cells by Spike pseudotyped lentiviral particles. ~2.5x10⁵ HEK-Blue™ Null1-v and HEK-Blue™ hACE2 cells were cultured in the presence of SARS-CoV-2 Spike (D614)-pseudotyped GFP lentiviral particles. The particles were generated using InvivoGen's pLV-Spike plasmid. After 72 hr, the transduction efficiency of the Spike pseudotyped GFP particles was evaluated by fluorescence microscopy.

hACE2 and TMPRSS2 mRNA expression. Total mRNA was extracted from ~5x105 HEK‑Blue™ Null1-v and HEK-Blue™ hACE2‑TMPRSS2 cells. ACE2 and TMPRSS2 mRNA were amplified using quantitative RT-qPCR. Data are represented as the log₂ fold change comparing hACE2 or TMPRSS2 relative expression between the cell lines.

Surface expression of hACE2. ~5x10⁵ HEK-Blue™ Null1-v and HEK-Blue™ hACE2-TMPRSS2 cells were incubated with 1 μg of Spike-S1-Fc or CTLA-4-Fc fusion proteins for 1 hr at 4°C. Cells were then washed and incubated with 0.5 μg of a goat anti-hIgG1-Fc antibody coupled to PE for 1 hr at 4°C. Cell surface staining was analyzed by flow cytometry.

Infection of HEK-Blue™ hACE2-TMPRSS2 cells by Spike pseudotyped lentiviral particles. ~2.0x10⁴ HEK-Blue™ Null1-v, HEK-Blue™ hACE2, and HEK-Blue™ hACE2-TMPRSS2 cells were cultured in the presence of Spike-pseudotyped GFP lentiviral particles. After 72h, the transduction efficiency of the Spike pseudotyped GFP particles was evaluated by flow cytometry.

Assessing cell fusion with 293-hMyD88 cells. 293-hMyD88 cells were transiently transfected with a SARS-CoV-2 Spike expression plasmid (pUNO1-Spike) using LyoVec™. After 24 hours, the cells were washed, and a dilution series of the ‘donor’ 293-hMyD88-Spike cells were co‑cultured with either 2.0 x10⁴ HEK‑Blue™ Null1-v, HEK-Blue™ hACE2, or HEK‑Blue™ hACE2-TMPRSS2 cells. After overnight incubation, cell fusion was assessed by measuring the activity of SEAP in the supernatant using QUANTI-Blue™ Solution, a SEAP detection reagent. Data are presented as OD630nm ± SEM.

Specifications

Growth medium: DMEM, 4.5 g/L glucose, 2 mM L-glutamine, 10% (v/v) heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin, 100 µg/ml streptomycin, 100 µg/ml Normocin™

Antibiotic resistance:

• HEK-Blue™ hACE2: Puromycin and  Zeocin®
• HEK-Blue™ hACE2-TMPRSS2: Hygromycin B Gold, Puromycin and Zeocin®

Quality Control 

• ACE2 gene expression has been verified by RT-qPCR, FACS staining, and functional assays.
• TMPRSS2 gene expression has been verified by RT-qPCR and functional assays.
• Activation of the NF-κB response has been verified upon stimulation with various inducers (e.g. TNF-α).
• The stability for 20 passages, following thawing, has been verified for HEK-Blue™ hACE2 and HEK-Blue™ hACE2-TMPRSS2
• These cells are guaranteed mycoplasma-free. 

InvivoGen's products are covered by a Limited Use License (See Terms and Conditions).

Contents

Please note: Each cell line is sold separately. See TDS for the exact contents of each cell line.

HEK-Blue™ hACE2 cells

• 3-7 x 10⁶ HEK-Blue™ hACE2 cells in a cryovial or shipping flask
• 1 ml of Puromycin (10 mg/ml)
• 1 ml of Zeocin® (100 mg/ml)
• 1 ml of Normocin™ (50 mg/ml). Normocin™ is a formulation of three antibiotics active against mycoplasmas, bacteria, and fungi.
• 1 ml of QB reagent and 1 ml of QB buffer (sufficient to prepare 100 ml of QUANTI-Blue™ Solution, a SEAP detection reagent)

HEK-Blue™ hACE2-TMPRSS2 cells

• 3-7 x 10⁶ HEK-Blue™ hACE2-TMPRSS2 cells in a cryovial or shipping flask
• 1 ml of Puromycin (10 mg/ml)
• 1 ml of Hygromycin B Gold (100 mg/ml)
• 1 ml of Zeocin® (100 mg/ml)
• 1 ml of Normocin™ (50 mg/ml). Normocin™ is a formulation of three antibiotics active against mycoplasmas, bacteria, and fungi.
• 1 ml of QB reagent and 1 ml of QB buffer (sufficient to prepare 100 ml of QUANTI-Blue™ Solution, a SEAP detection reagent)

Shipped on dry ice (Europe, USA & Canada)

Details

ACE2 BACKGROUND

ACE2 plays a critical role in the pathogenesis of coronavirus disease-19 (COVID-19) caused by SARS-CoV-2 (2019-nCoV) by facilitating viral entry through its interaction with the Spike receptor-binding domain (RBD) [1]. Following this, host proteases (e.g. transmembrane protease serine 2 (TMPRSS2)) cleave the S protein into two functional subunits (S1 and S2), allowing virus-host membrane fusion, and the release of viral contents (e.g. RNA) into the cytosol [1-3]. Notably, TMPRSS2 is not needed for infection of HEK293 cells by SARS-CoV-2 spike-pseudotyped lentiviral particles [4, in-house data].

References

1. Zhou P. et al., 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 579(7798):270-273.
2. Hoffmann M. et al., 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 181:1-16.
3. Walls A.C. et al., 2020. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 181(2):281-292.e6.
4. Korber B. et al., 2020. Tracking changes in SARS-CoV-2-Spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. DOI: 10.1016/j.cell.2020.06.043.

FAQ Cell Lines

Any questions about our cell lines ? Visit our frequently asked questions page